Results 191 to 200 of about 5,260,709 (398)
Ovarian Cancer Diagnostics using Wavelet Packet Scaling Descriptors [PDF]
arXivDetecting early-stage ovarian cancer accurately and efficiently is crucial for timely treatment. Various methods for early diagnosis have been explored, including a focus on features derived from protein mass spectra, but these tend to overlook the complex interplay across protein expression levels.
arxiv
Feature Selection for Data Integration with Mixed Multi-view Data [PDF]
arXiv, 2019 Data integration methods that analyze multiple sources of data simultaneously can often provide more holistic insights than can separate inquiries of each data source. Motivated by the advantages of data integration in the era of "big data", we investigate feature selection for high-dimensional multi-view data with mixed data types (e.g.
arxiv
NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019.
The Journal of the National Comprehensive Cancer Network, 2019 Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the United States, with less than half of patients living >5 years from diagnosis. A major challenge in treating ovarian cancer is that most patients have advanced disease
D. Armstrong +31 more
semanticscholar +1 more source
Advanced Healthcare Materials, EarlyView.Schematic illustration of the mechanism of targeted delivery of nanoparticles including 1) paracellular, 2) endolysosomal escape, 3) receptor mediated endocytosis, and 4) M cell mediated transport for non‐GI diseases by oral administration such as atherosclerosis, cancer, diabetes, and brain diseases. Abstract Oral drug delivery is a promising approach
Subarna Ray +2 more
wiley +1 more source
Benchmarking Histopathology Foundation Models for Ovarian Cancer Bevacizumab Treatment Response Prediction from Whole Slide Images [PDF]
arXivBevacizumab is a widely studied targeted therapeutic drug used in conjunction with standard chemotherapy for the treatment of recurrent ovarian cancer. While its administration has shown to increase the progression-free survival (PFS) in patients with advanced stage ovarian cancer, the lack of identifiable biomarkers for predicting patient response has
arxiv
Epigenetic therapy for ovarian cancer: promise and progress
Clinical Epigenetics, 2019 Ovarian cancer is the deadliest gynecologic malignancy, with a 5-year survival rate of approximately 47%, a number that has remained constant over the past two decades.
Sara Moufarrij +7 more
semanticscholar +1 more source
Advanced Healthcare Materials, EarlyView.This study developed a biomimetic scaffold incorporating PDRN and melatonin to restore ovarian function in chemotherapy‐induced premature ovarian insufficiency, enhancing cell survival, folliculogenesis, and hormone normalization, while improving fertility rates and offspring in a mouse model, offering a promising strategy for ovarian function ...
Da‐Seul Kim +8 more
wiley +1 more source
Lymphocyte response to autologous tumor antigen(S) and phytohemagglutinin in ovarian cancer patients [PDF]
, 1975 Malaya Chatterjee +4 more
openalex +1 more source
Advanced Healthcare Materials, EarlyView.Minimal residual disease (MRD) leads to cancer relapse and poor survival in ovarian cancer. The lack of representative 3D models limits therapy development. The microfluidics‐based high throughput 3D microtumor platform described here generates clinically‐relevant MRD models. The 3D microtumors recapitulate the molecular signatures of MRD from patients.
Xingyun Yang +14 more
wiley +1 more source